Liquid-Based Cytology (LBC)

In 1996, a major event in the history of the Pap Test occurred when the FDA approved the ThinPrep® Pap test (Hologic Inc.) as an alternative to the conventional cervicovaginal smear. This was followed 3 years later by the approval of AutoCyteTM Prep, now SurePathTM (Becton Dickinson Inc.). These are the two first liquid-based cytology technologies approved for cervical cancer screening in the United States.